Company research
Design Therapeutics, Inc.
CIK 1807120Updated Sep 26, 2026
SecurityDSGN · NASDAQ · equity
DSGN price & chart
Loading TradingView…
NASDAQ:DSGN on TradingView ↗About the company
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
In the news
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 226,203,000Source | 252,093,000Source | 289,643,000Source | 341,137,000Source |
| Property, Plant and Equipment, NetUSD | 981,000Source | 1,410,000Source | 1,691,000Source | 1,947,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,856,000Source | 22,563,000Source | 21,200,000Source | 26,500,000Source |
| Assets, CurrentUSD | 223,784,000Source | 248,040,000Source | 284,584,000Source | 335,119,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,939,000Source | 2,563,000Source | 2,786,000Source | 4,732,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,438,000Source | 2,216,000Source | 2,938,000Source | 3,612,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 13,700,000Source | 9,996,000Source | 11,956,000Source | 13,827,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | -297,006,000Source | -227,214,000Source | -177,626,000Source | -110,764,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 403,000Source | 475,000Source | 62,000Source | -3,356,000Source |
| Stockholders' Equity Attributable to ParentUSD | 212,503,000Source | 242,097,000Source | 277,687,000Source | 327,310,000Source |
| Additional Paid in Capital, Common StockUSD | 509,100,000Source | 468,830,000Source | 455,245,000Source | 441,424,000Source |
| Liabilities and EquityUSD | 226,203,000Source | 252,093,000Source | 289,643,000Source | 341,137,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 13,055,000Source | 8,462,000Source | 9,622,000Source | 10,776,000Source |
| Operating Lease, Liability, CurrentUSD | 890,000Source | 800,000Source | 716,000Source | 640,000Source |
| Accounts Payable, CurrentUSD | 2,312,000Source | 2,186,000Source | 1,940,000Source | 3,025,000Source |
| Operating Lease, Liability, NoncurrentUSD | 645,000Source | 1,534,000Source | 2,334,000Source | 3,051,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 10,743,000Source | 6,276,000Source | 7,682,000Source | 7,751,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 219,800,000Source | 245,500,000Source | 281,800,000Source | 330,400,000Source |
| Deferred Tax Liabilities, NetUSD | 546,000Source | 836,000Source | 975,000Source | 1,168,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,549,000Source | 13,072,000Source | 13,088,000Source | 10,925,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -54,358,000Source | -43,105,000Source | -58,560,000Source | -51,317,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 22,913,000Source | 43,955,000Source | 52,536,000Source | -220,987,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 193,000Source | 340,000Source | 256,000Source | 918,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 25,738,000Source | 513,000Source | 724,000Source | 235,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,707,000Source | 1,363,000Source | -5,300,000Source | -272,069,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 16,856,000Source | 22,563,000Source | 21,200,000Source | 26,500,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,549,000Source | 13,072,000Source | 13,088,000Source | 10,925,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 219,800,000Source | 245,500,000Source | 281,800,000Source | 330,400,000Source |
| DepreciationUSD | 622,000Source | 596,000Source | 537,000Source | 406,000Source |
| General and Administrative ExpenseUSD | 20,338,000Source | 18,033,000Source | 21,127,000Source | 18,980,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 9,675,000Source | 12,795,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Operating ExpensesUSD | 79,467,000Source | 62,383,000Source | 78,190,000Source | 67,593,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 11,328,000Source | 4,285,000Source |
| Payments to Acquire InvestmentsUSD | 291,779,000Source | 230,175,000Source | 224,703,000Source | 312,998,000Source |
| Proceeds from Issuance of Common StockUSD | 24,847,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 242,000Source | 36,000Source | 419,000Source | 323,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | — | — |
| Operating Income (Loss)USD | -79,467,000Source | -62,383,000Source | -78,190,000Source | -67,593,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 11,328,000Source | 4,285,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Earnings Per Share, BasicUSD per share | -1.22Source | -0.88Source | -1.19Source | -1.14Source |
| Earnings Per Share, DilutedUSD per share | -1.22Source | -0.88Source | -1.19Source | -1.14Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 57,330,192Source | 56,587,142Source | 55,984,670Source | 55,707,517Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 57,330,192Source | 56,587,142Source | 55,984,670Source | 55,707,517Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 20,338,000Source | 18,033,000Source | 21,127,000Source | 18,980,000Source |
| Investment Income, InterestUSD | 9,675,000Source | 12,795,000Source | — | — |
| Operating ExpensesUSD | 79,467,000Source | 62,383,000Source | 78,190,000Source | 67,593,000Source |
| Research and Development ExpenseUSD | 59,129,000Source | 44,350,000Source | 57,063,000Source | 48,613,000Source |
Filing attachments
dsgn-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong fi…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2026-04-28
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution Carlsbad, Calif., April 28, 2026 - Design Th…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2026-03-09
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution Carlsbad, Calif., March 9, 2026 - Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology compa…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2025-11-05
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2025-08-07
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from non-human primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker Study for DT-168 …
Read attachment ↗